HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00034892

Three antipsychotic medicines for a first episode of psychosis

About this titleRead the official source — NCT00034892
Medication studyAges 16–40United States + CanadaSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 16 years to 40 years.

Listed locations
Stanford and 25 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMarch 2002
Recruitment status
Completed
Enrollment listed in the registry
Not clearly listed
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Canada
Age range
From 16 Years to 40 Years
Official registry ID
NCT00034892
Official title
Show the full official title

Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Stanford, United States · Miami, United States · Atlanta, United States

23 more locations
  • Augusta, United States
  • Chicago, United States
  • Shreveport, United States
  • Boston, United States
  • Worcester, United States
  • Minneapolis, United States
  • St Louis, United States
  • Las Vegas, United States
  • Brooklyn, United States
  • New York, United States
  • Butner, United States
  • Chapel Hill, United States
  • Charlotte, United States
  • Cincinnati, United States
  • Cleveland, United States
  • Kettering, United States
  • Philadelphia, United States
  • Conroe, United States
  • Dallas, United States
  • San Antonio, United States
  • Salt Lake City, United States
  • Calgary, Canada
  • Halifax, Canada

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Olanzapine, risperidone.

Who was this study for?

Listed age limits: 16 years to 40 years.

Want to explore more studies?

Explore studies